125 related articles for article (PubMed ID: 12369969)
41. Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants.
Becker DA; Ley JJ; Echegoyen L; Alvarado R
J Am Chem Soc; 2002 May; 124(17):4678-84. PubMed ID: 11971716
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and Biological Evaluation of Curcumin-Nitroxide-Based Molecular Hybrids as Antioxidant and Anti-Proliferative Agents.
Bognar B; Kuppusamy ML; Madan E; Kalai T; Balog M; Jeko J; Kuppusamy P; Hideg K
Med Chem; 2017; 13(8):761-772. PubMed ID: 28530545
[TBL] [Abstract][Full Text] [Related]
43. Targeting tumors with hypoxia-activated cytotoxins.
Ahn GO; Brown M
Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
[TBL] [Abstract][Full Text] [Related]
44. Redox generation of nitric oxide to radiosensitize hypoxic cells.
Mitchell JB; DeGraff W; Kim S; Cook JA; Gamson J; Christodoulou D; Feelisch M; Wink DA
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):795-8. PubMed ID: 9845098
[TBL] [Abstract][Full Text] [Related]
45. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
46. Development of hypoxia selective cytotoxins for cancer treatment: an update.
Cerecetto H; González M; Lavaggi ML
Med Chem; 2006 May; 2(3):315-27. PubMed ID: 16948479
[TBL] [Abstract][Full Text] [Related]
47. Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Gargano EM; Perspicace E; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Bioorg Med Chem Lett; 2016 Jan; 26(1):21-4. PubMed ID: 26615885
[TBL] [Abstract][Full Text] [Related]
48. Novel semisynthetic spin-labeled derivatives of podophyllotoxin with cytotoxic and antioxidative activity.
Zhang JQ; Zhang ZW; Hui L; Chen SW; Tian X
Bioorg Med Chem Lett; 2010 Feb; 20(3):983-6. PubMed ID: 20053564
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Wilson WR; Anderson RF; Denny WA
J Med Chem; 1996 Mar; 39(5):1084-94. PubMed ID: 8676343
[TBL] [Abstract][Full Text] [Related]
50. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.
Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA
J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864
[TBL] [Abstract][Full Text] [Related]
51. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
52. Total synthesis and cytotoxicity evaluation of all ochratoxin A stereoisomers.
Cramer B; Harrer H; Nakamura K; Uemura D; Humpf HU
Bioorg Med Chem; 2010 Jan; 18(1):343-7. PubMed ID: 19919898
[TBL] [Abstract][Full Text] [Related]
53. Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction.
Denny WA; Wilson WR; Tercel M; Van Zijl P; Pullen SM
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):317-21. PubMed ID: 8195026
[TBL] [Abstract][Full Text] [Related]
54. Efficient one-pot synthesis of biologically active polysubstituted aromatic amines.
Menche D; Arikan F; Li J; Rudolph S; Sasse F
Bioorg Med Chem; 2007 Dec; 15(23):7311-7. PubMed ID: 17870540
[TBL] [Abstract][Full Text] [Related]
55. 1, 2, 4-Triazine N-oxide derivatives: studies as potential hypoxic cytotoxins. Part III.
Cerecetto H; González M; Risso M; Saenz P; Olea-Azar C; Bruno AM; Azqueta A; De Ceráin AL; Monge A
Arch Pharm (Weinheim); 2004 May; 337(5):271-80. PubMed ID: 15095420
[TBL] [Abstract][Full Text] [Related]
56. Antioxidant action of a lipophilic nitroxyl radical, cyclohexane-1-spiro-2'-(4'-oxyimidazolidine-1'-oxyl) -5'-spiro-1"-cyclohexane, against lipid peroxidation under hypoxic conditions.
Shimakawa S; Yoshida Y; Niki E
Lipids; 2003 Mar; 38(3):225-31. PubMed ID: 12784862
[TBL] [Abstract][Full Text] [Related]
57. Potential therapeutic applications of metal compounds directed towards hypoxic tissues.
Gambino D
Curr Med Chem; 2010; 17(31):3616-31. PubMed ID: 20846115
[TBL] [Abstract][Full Text] [Related]
58. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Walton MI; Sugget N; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
[TBL] [Abstract][Full Text] [Related]
59. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
60. Anti-inflammatory, analgesic and antioxidant activities of novel kyotorphin-nitroxide hybrid molecules.
Bi W; Bi Y; Gao X; Yan X; Zhang Y; Xue P; Bammert CE; Legalley TD; Michael Gibson K; Bi L; Wang JX
Bioorg Med Chem Lett; 2016 Apr; 26(8):2005-13. PubMed ID: 26961795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
